Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06532942 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MKND-201 in Healthy Volunteers

A Phase 1 study of Healthy Volunteers, sponsored by Mannkind Corporation.

Recruiting
Registry status
Phase 1
Development phase
40
Enrollment target
1
Study location

NCT06532942 is a Phase 1 study of Healthy Volunteers that is actively recruiting participants, run by Mannkind Corporation. The registered enrollment target is 40 participants, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06532942, a Phase 1 study of Healthy Volunteers, is actively recruiting participants, sponsored by Mannkind Corporation.

RECRUITING
Registry status
Phase 1
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

MKC-NI-001 is a Phase 1, first-in-human, randomized, double-blind, placebo-controlled study of nintedanib inhalation powder (MNKD-201) in healthy adult volunteers. The trial consists of a Single Ascending Dose (SAD), followed by a Multiple Ascending Dose (MAD) with a primary objective to evaluate the safety, tolerability, and pharmacokinetics (PK) of MNKD-201 compared to placebo in healthy adult participants.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG (Part A) MKND-201
  • DRUG (Part B) MKND-201

Study Locations (1)

Texas

  • Flourish Research - San Antonio

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2024-05-28
Est. Completion 2024-10-31
Phase Phase 1

Sponsor

Mannkind Corporation

42 total trials

What the Registry Record Tells You About NCT06532942

The ClinicalTrials.gov registry entry for NCT06532942 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (92% lower). The listed sponsor is Mannkind Corporation, which has 42 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT06532942 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT06532942 about?

NCT06532942 is a clinical study titled "A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MKND-201 in Healthy Volunteers". MKC-NI-001 is a Phase 1, first-in-human, randomized, double-blind, placebo-controlled study of nintedanib inhalation powder (MNKD-201) in healthy adult volunteers. The trial consists of a Single Ascending Dose (SAD), followed by a Multiple Ascending Dose (MAD) with a primary objective to evaluate th...

What is the current status of trial NCT06532942?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2024-05-28. Estimated completion is 2024-10-31.

What conditions does trial NCT06532942 study?

This clinical trial studies the following conditions: Healthy Volunteers.

What interventions are being tested in trial NCT06532942?

The interventions under investigation include: Placebo (DRUG), (Part A) MKND-201 (DRUG), (Part B) MKND-201 (DRUG).

Who is sponsoring clinical trial NCT06532942?

This trial is sponsored by Mannkind Corporation, which has 42 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06532942 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteers

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.